Rodin Therapeutics is a biotechnology company developing therapies for neurological disorders by applying insights gained from epigenetics. The company was founded by Ankit Mahadevia and Martin Jefson in 2013, and is headquartered in Cambridge, Massachusetts.
On June 27, 2013 Rodin Therapeutics closed their seed funding round with an undisclosed amount of funding from Johnson & Johnson Development Corporation and Atlas Venture.
On May 29, 2014 Rodin Therapeutics closed their series A funding round raising $12.9 million is funding from Johnson & Johnson Development Corporation and Atlas Venture.
On January 6, 2016 Rodin Therapeutics closed their series B funding round raising $17.3 million in funding from Biogen Idec and Atlas Ventures.
On September 18, 2017 Rodin Therapeutics closed their series C funding round raising $27 million in funding from Third Point Ventures, Remeditex Ventures, Hatteras Venture Partners, GV, and Atlas Ventures. In addition to closing their series C funding round Rodin Therapeutics appointed three new members to their Board of Directors.
Oryzon Genomics Develops Epigenetic Treatment for Alzheimer's
Rodin Therapeutics Announces Initiation of Phase 1 Clinical Trial of a Selective CoREST Inhibitor to Treat Neurologic Diseases
Trial to Test New Imaging Agent for Visualizing Synapses in Living Brain
Documentaries, videos and podcasts
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.